Drug pricing: No cure, no cost.
Jack
Andrew
A
Financial Times, London. Andrew.Jack@ft.com
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D035841:Behavioral Research / Q000191:economics; D001897:Boronic Acids / Q000191:economics / Q000627:therapeutic use*; D000069286:Bortezomib; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D007400:Interprofessional Relations; D040541:Marketing; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000191:economics; D011719:Pyrazines / Q000191:economics / Q000627:therapeutic use*; D012074:Remission Induction; D013222:State Medicine / Q000191:economics; D017211:Treatment Failure; D006113:United Kingdom
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib